185 related articles for article (PubMed ID: 34019619)
1. Nonhuman glycans can regulate anti-factor VIII antibody formation in mice.
Arthur CM; Zerra PE; Shin S; Wang J; Song X; Doering CB; Lollar P; Meeks S; Stowell SR
Blood; 2022 Mar; 139(9):1312-1317. PubMed ID: 34019619
[TBL] [Abstract][Full Text] [Related]
2. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
3. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.
Afonja O; Kozak R; Petraro P; Michaels LA; Mathew P; Lemm G; Kessler C
Expert Rev Hematol; 2016 Dec; 9(12):1151-1164. PubMed ID: 27841041
[TBL] [Abstract][Full Text] [Related]
4. N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice.
Lai JD; Swystun LL; Cartier D; Nesbitt K; Zhang C; Hough C; Dennis JW; Lillicrap D
Haematologica; 2018 Nov; 103(11):1925-1936. PubMed ID: 30002126
[TBL] [Abstract][Full Text] [Related]
5. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
[TBL] [Abstract][Full Text] [Related]
6. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.
Hausl C; Ahmad RU; Sasgary M; Doering CB; Lollar P; Richter G; Schwarz HP; Turecek PL; Reipert BM
Blood; 2005 Nov; 106(10):3415-22. PubMed ID: 16091456
[TBL] [Abstract][Full Text] [Related]
7. Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation.
Zerra PE; Arthur CM; Chonat S; Maier CL; Mener A; Shin S; Allen JWL; Baldwin WH; Cox C; Verkerke H; Jajosky RP; Tormey CA; Meeks SL; Stowell SR
Front Immunol; 2020; 11():905. PubMed ID: 32582142
[TBL] [Abstract][Full Text] [Related]
8. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
9. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
[TBL] [Abstract][Full Text] [Related]
10. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
[TBL] [Abstract][Full Text] [Related]
11. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.
Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
Thromb Haemost; 2009 Jul; 102(1):35-41. PubMed ID: 19572065
[TBL] [Abstract][Full Text] [Related]
12. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.
Lai J; Hough C; Tarrant J; Lillicrap D
Blood; 2017 Jun; 129(24):3147-3154. PubMed ID: 28432221
[TBL] [Abstract][Full Text] [Related]
13. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
Chen Y; Schroeder JA; Chen J; Luo X; Baumgartner CK; Montgomery RR; Hu J; Shi Q
Blood; 2016 Mar; 127(10):1346-54. PubMed ID: 26668132
[TBL] [Abstract][Full Text] [Related]
14. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
[TBL] [Abstract][Full Text] [Related]
15. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.
Lai JD; Moorehead PC; Sponagle K; Steinitz KN; Reipert BM; Hough C; Lillicrap D
Blood; 2016 Jun; 127(26):3439-49. PubMed ID: 27034428
[TBL] [Abstract][Full Text] [Related]
16. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
[TBL] [Abstract][Full Text] [Related]
17. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
Wroblewska A; van Haren SD; Herczenik E; Kaijen P; Ruminska A; Jin SY; Zheng XL; van den Biggelaar M; ten Brinke A; Meijer AB; Voorberg J
Blood; 2012 May; 119(22):5294-300. PubMed ID: 22498747
[TBL] [Abstract][Full Text] [Related]
18. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A.
Reipert BM; Ahmad RU; Turecek PL; Schwarz HP
Thromb Haemost; 2000 Nov; 84(5):826-32. PubMed ID: 11127864
[TBL] [Abstract][Full Text] [Related]
19. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.
Peyvandi F; Miri S; Garagiola I
Front Immunol; 2020; 11():591878. PubMed ID: 33552050
[TBL] [Abstract][Full Text] [Related]
20. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.
Gangadharan B; Delignat S; Ollivier V; Gupta N; Mackman N; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2014 Dec; 12(12):2065-9. PubMed ID: 25267332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
